RTI Biologics, Inc. (RTIX) Tops Q2 EPS by 1c; Boosts FY11 Estimates; Guides Q3
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Price: $3.14 --0%
Financial Fact:
Foreign exchange (loss) gain: -67K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Foreign exchange (loss) gain: -67K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
RTI Biologics, Inc. (NASDAQ: RTIX) reported Q2 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $43.5 million versus the consensus estimate of $40.48 million.
RTI Biologics, Inc. sees FY2011 EPS of $0.12-$0.14, versus prior guidance of $0.11-$0.13 and the consensus of $0.12. RTI Biologics, Inc. sees FY2011 revenue of $164-$166 million, versus prior guidance of $159-$162 million and the consensus of $161.79 million.
RTI Biologics, Inc. sees Q3 2011 EPS of $0.03, versus the consensus of $0.03. RTI Biologics, Inc. sees Q3 2011 revenue of $40-$41 million, versus the consensus of $38.98 million.
RTI Biologics, Inc. sees FY2011 EPS of $0.12-$0.14, versus prior guidance of $0.11-$0.13 and the consensus of $0.12. RTI Biologics, Inc. sees FY2011 revenue of $164-$166 million, versus prior guidance of $159-$162 million and the consensus of $161.79 million.
RTI Biologics, Inc. sees Q3 2011 EPS of $0.03, versus the consensus of $0.03. RTI Biologics, Inc. sees Q3 2011 revenue of $40-$41 million, versus the consensus of $38.98 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Movano (MOVE) Misses Q2 EPS by 195c
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
